查詢結果分析
來源資料
相關文獻
- Large Renal Cell Carcinoma with Multiple Metastases Presenting as Low Back Pain
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- 胃腸道基質瘤之治療
- 晚期腎細胞癌之標靶治療
- 非小細胞肺癌的標靶治療
- A Case of Metastatic Renal Cell Carcinoma with Acute Airway Obstruction and Difficulty Performing an Endobronchial Technique Solved Using an Angiogenesis Inhibitor
- 標靶治療--癌症治療新境界
- 慢性骨髓性白血病治療之最新進展
- Crizotinib與分子病理學的檢測
- 多發性骨髓瘤最新治療簡介
頁籤選單縮合
題名 | Large Renal Cell Carcinoma with Multiple Metastases Presenting as Low Back Pain=左側巨大之腎細胞癌併多處轉移以下背痛為初始表現 |
---|---|
作者姓名(中文) | 林瑜茵; 黃炯棠; 卓士峯; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 1:1 2014.06[民103.06] |
頁次 | 頁63-69 |
分類號 | 416.273 |
關鍵詞 | 轉移性腎細胞癌; 標靶治療; 酪胺酸激酶抑制劑; Metastatic renal cell carcinoma; Target therapy; Tyrosine kinase inhibitor; |
語文 | 英文(English) |
中文摘要 | 腎細胞癌是一個高致命性的泌尿系統惡性腫瘤,原因包含了早期疾病不易診斷以及 晚期轉移性腎細胞對傳統化學治療、免疫治療及放射線治療有高度抗性。但近幾年對腎 細胞癌的分子致病機轉有更透徹之了解,尤其是透明細胞型腎細胞癌具有 VHL 抑癌基因 的異常,導致下游血管內皮生長因子等與血管新生有關的基因活化而造成腫瘤。針對上述與血管新生有關分子接受器之標靶治療,改善病人的預後,也改變了轉移性腎細胞癌 之治療方式。 我們報告一位年輕的女性被診斷出轉移性的腎細胞癌,但是初始的表現是下背痛, 經過一系列檢查才發現有一個巨大的左側腎臟腫瘤以及多處肝和骨頭的轉移。這位病人 使用口服標靶治療來控制病情,目前仍然在治療中。 雖然腎細胞癌的治療進入了分子標靶的新時代,但還是有一些值得探討的課題,我 們也回顧相關的一些文獻。 |
英文摘要 | Renal cell carcinoma (RCC) is a highly lethal genitourinary malignancy due to infrequent early diagnosis, which responds poorly to conventional immune therapy, chemotherapy or radiotherapy in metastatic disease. There have been great advances in the understanding of the molecular mechanisms of RCC in recent years, especially with regards to dysfunction of the Von Hippel–Lindau tumor suppressor gene in clear cell type RCC. This dysfunction has been shown to result in the activation of downstream angiogenesis related genes such as vascular endothelial growth factor. Treatment targeting this molecular pathway has been shown to improve patient prognosis and has become the standard treatment for metastatic clear cell RCC. Herein, we report a case of advanced and metastatic RCC initially presenting as low-back pain, but without the typical symptoms. Physical, laboratory and imaging examinations revealed a large left kidney tumor and multiple metastases to the liver and bones. The patient received oral tyrosine kinase inhibitor target therapy with a good tumor response. Treatment of RCC has entered the era of molecular target therapy, however some issues still need to be addressed, such as the safety issue of tyrosine kinase inhibitor and role of cytoreductive surgery. We also review related articles and have some discussion. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。